Criteria to qualify for study: Drug used in study:
  • Now only enrolling PTCL. Must have failed 1 prior therapy and Have 1 site of measurable disease.

HR 43

A phase 1a/1b dose escalation trial of single agent TTl-621, a novel biologic targeting CD47, in subjects with relapsed of refractory hematologic malignancies.
Criteria to qualify for study: Drug used in study:
  • Relapsed of refractory multiple myeloma or relapsed of refractory B-Cell NHL after at least 2 prior regimens.

HR 59

A phase 1a/1b open label, multicenter study evaluating the safety and pharmacokinetics of Tiragolumab as a single agent and in combination with Daratumumab in patients with relapsed or refractory Multiple Myeloma, and as a single agent and in combination with Rituximab in patients with relapsed of refractory B-Cell Non Hodgkin Lymphoma.
Criteria to qualify for study: Drug used in study:
  • At least 2 lines of prior therapies including an anthracycline and an anti-CD20 monoclonal antibody.

LYM 151

A Single-Arm, open –label phase ½ study evaluating the safety and efficacy and Cellular Kinetics/Pharmacodynamics of ALLO-501, an Anti-CD19 Allogeneic CAR-T Cell Therapy in patients with relapsed/refractory Large B-Cell and Follicular Lymphoma.
Criteria to qualify for study: Drug used in study:
  • Relapsed of refractory after at least 2 prior lines of therapy including rituximab and alkylating agents. Includes follicular NHL, MZL, WM, SLL

LYM 145

Efficacy and safety stuydy of Tenalisib (RP6530), a novel PI3K dual inhibitor in Patients with relapsed/refractory indolent Non-Hodgkin Lymphoma (iNHL).
Criteria to qualify for study: Drug used in study:
  • Treated with an anthracycline and anti CD20 agent; relapsed or refractory disease after at least 2 lines of therapy or autologous stem cell transplant.

LYM 146

A safety trial of Lisocabtagene Maraleucel (JCAR017) for relapsed and refractory (R/R) B-Cell Non – Hodgkin Lymphoma (NHL) in the outpatient setting.
Criteria to qualify for study: Drug used in study:
  • Relapsed of refractory B-Cell NHL after front line therapy.

LYM 147

Tisagenlecleucel versus standard of care in adult patients with relapsed of refractory aggressive B-CELL Non-Hodgkin Lymphoma. A randomized, open label phase lll trial (BELINDA).
Criteria to qualify for study: Drug used in study:
  • DLBCL, Relapsed or Refractory

LYM 120 TG Therapeutics UTX-TGR-205

A Phase 2b Randomized Study to assess the efficacy and safety of the combination of Ublituximab + TGR-1202 and TGR-1202 alone in patients with previously treated Diffuse Large B-Cell Lymphoma
Criteria to qualify for study: Drug used in study:
  • Prior allogeneic HCT history or presence of CNS pathology or involvement

LYM 140

A Single Arm, Open label, multi-center Phase I/II study evaluating the safety and clinical activity of AUTO3, a CAR-T Cell treatment targeting CD19 and CD22 and consolidation with Anti-PD1 Antibody in patients with relapsed of refractory Diffuse Large B Cell Lymphoma.
Criteria to qualify for study: Drug used in study:
  • Relapsed / Refractory
  • 2 part, multicenter, open label, phase 1a/1b study of TTI-622 in patients with advanced relapsed or refractory lymphoma and multiple myeloma

HR 56 TTI-622-01

A Phase 1a/1b dose escalation and expansion trial of TTI-622 in patients with Advanced Relapsed or Refractory Lymphoma or Myeloma.